2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|June 17, 2019
Lonza Expands HPAPI Capacity
Author(s)Pharmaceutical Technology Editors
Two additional production lines expand Lonza’s HPAPI capacity at Visp, Switzerland facility.
Advertisement
Lonza announced on June 13, 2019 plans to add two production lines in an expansion of the company’s highly potent API (HPAPI) capacity at its Visp, Switzerland site to meet increased market demand. The announced investment will add two 4-m3-scale, multi-purpose lines to the company’s existing capabilities for lab- to large commercial-scale HPAPI production.
The new lines are expected to be online by July 2020, the company reported in a press statement. In addition, the company said it plans to improve flexibility in existing production lines, to improve time-to-market and accelerate approval timelines for partners.
The company reports that the facility will support the delivery of products from AstraZeneca portfolio under a long-term manufacturing agreement. The remaining capacity will be available to other clients.
“We are delighted to support one of our strategic partners in securing supply of innovative therapies for the treatment of cancer patients,” said Lee Newton, vice-president and API business unit head, Lonza Pharma & Biotech. “Oncology continues as the leading indication in biopharma and we will continue to invest to meet the HPAPI development and manufacturing needs of our customers.”
Source:
Advertisement
Related to this article
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement